Completed PHASE2 INTERVENTIONAL NCT00320450

SB-681323 In Subjects With Rheumatoid Arthritis

A Randomised, Parallel Group, Placebo-controlled, Double Blind Study to Assess the Safety and Tolerability of SB-681323 at 7.5mg Daily Dose for 28 Days and Its Effect on the Levels of Serum C-reactive Protein (CRP) in Subjects With Rheumatoid Arthritis (RA)

Sponsor: GlaxoSmithKline

Conditions Arthritis, Rheumatoid

Interventions SB-681323

Updated 6 times since 2017 Last updated: Oct 31, 2013 Started: Nov 30, 2005 Primary completion: Oct 31, 2006 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00320450, this PHASE2 trial focuses on Arthritis, Rheumatoid and remains completed. Sponsored by GlaxoSmithKline, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Augsburg, Germany , Baracaldo/Vizcaya, Spain , Benevento, Italy , Drammen, Norway , Edinburgh, United Kingdom , Foggia, Italy , Frankfurt am Main, Germany , Gothenburg, Sweden , Granada, Spain and 29 more locations